Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: A randomized clinical trial

JAMA Psychiatry

Volumn 72, Issue 3, 2015, Pages 235-246

  McElroy, Susan L ^a,b   Hudson, James I ^c   Mitchell, James E ^d,e   Wilfley, Denise ^f   Ferreira Cornwell, M Celeste ^g   Gao, Joseph ^g   Wang, Jiannong ^g,h   Whitaker, Timothy ^g   JonasMD, Jeffrey ^g,i   Gasior, Maria ^g  

^a LINDNER CENTER OF HOPE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SHIRE   (United States)

^h CSL BEHRING   (United States)

ⁱ Sage Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISDEXAMFETAMINE; PLACEBO; DEXAMPHETAMINE; DOPAMINE UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; BINGE EATING DISORDER; BODY WEIGHT; BODY WEIGHT DISORDER; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SLEEP DISORDER; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; WEIGHT CHANGE; WEIGHT REDUCTION; XEROSTOMIA; BINGE-EATING DISORDER; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; BINGE-EATING DISORDER; DEXTROAMPHETAMINE; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84925354914     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.2162     Document Type: Article

References (66)

1. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61(3):348-358.
2. Hudson JI, Lalonde JK, Coit CE, et al. Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder. Am J Clin Nutr. 2010;91(6): 1568-1573.
3. McElroy SL, Guerdjikova AI, Mori N, O'Melia AM. Pharmacological management of binge eating disorder: current and emerging treatment options. Ther Clin Risk Manag. 2012;8:219-241.
4. Wilfley DE, Wilson GT, AgrasWS. The clinical significance of binge eating disorder. Int J Eat Disord. 2003;34(suppl):S96-S106.
5. Kessler RC, Berglund PA, Chiu WT, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904-914.
6. Mathes WF, Brownley KA,Mo X, Bulik CM. The biology of binge eating. Appetite. 2009;52(3):545-553.
7. Javaras KN, Pope HG, Lalonde JK, et al. Co-occurrence of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry. 2008;69(2):266-273.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
9. Berg KC, Stiles-Shields EC, Swanson SA, Peterson CB, Lebow J, Le Grange D. Diagnostic concordance of the interview and questionnaire versions of the Eating Disorder Examination. Int J Eat Disord. 2012;45(7):850-855.
10. Keel PK, Brown TA, Holm-Denoma J, Bodell LP. Comparison of DSM-IV versus proposed DSM-5 diagnostic criteria for eating disorders: reduction of eating disorder not otherwise specified and validity. Int J Eat Disord. 2011;44(6):553-560.
11. Iacovino JM, Gredysa DM, Altman M, Wilfley DE. Psychological treatments for binge eating disorder. Curr Psychiatry Rep. 2012;14(4):432-446.
12. Wilson GT,Wilfley DE, AgrasWS, Bryson SW. Psychological treatments of binge eating disorder. Arch Gen Psychiatry. 2010;67(1):94-101.
13. Capasso A, Petrella C, MilanoW. Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders. Curr Clin Pharmacol. 2009;4(1):78-83.
14. Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring). 2008;16(9):2024-2038.
15. Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry. 2003;60(11):1109-1116.
16. Wilfley DE, Crow SJ, Hudson JI, et al Sibutramine Binge Eating Disorder Research Group. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry. 2008;165(1):51-58.
17. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160 (2):255-261.
18. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR; Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039-1048.
19. McElroy SL, Guerdjikova AI, Martens B, Keck PE Jr, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 2009;23(2):139-156.
20. Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 2010;13(5):635-641.
21. ShinoharaM,Mizushima H, Hirano M, et al. Eating disorders with binge-eating behaviour are associated with the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene. J Psychiatry Neurosci. 2004;29(2):134-137.
22. Latagliata EC, Patrono E, Puglisi-Allegra S, Ventura R. Food seeking in spite of harmful consequences is under prefrontal cortical noradrenergic control. BMC Neurosci. 2010;11:15. doi:10.1186/1471-2202-11-15.
23. Stice E, Spoor S, Bohon C, Small DM. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science. 2008;322(5900):449-452.
24. Davis CA, Levitan RD, Reid C, et al. Dopamine for "wanting" and opioids for "liking": a comparison of obese adults with and without binge eating. Obesity (Silver Spring). 2009;17(6):1220-1225.
25. Davis C, Levitan RD, Kaplan AS, et al. Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder. Neuropsychopharmacology. 2007;32(10):2199-2206.
26. Rothemund Y, Preuschhof C, Bohner G, et al. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage. 2007;37(2):410-421.
27. Wang GJ, Geliebter A, Volkow ND, et al. Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity (Silver Spring). 2011;19(8):1601-1608.
28. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009; 57(7-8):608-618.
29. Vyvanse® (Lisdexamfetamine Dimesylate) [package insert].Wayne, PA: Shire US Inc; 2013.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision.Washington, DC: American Psychiatric Association; 2000.
31. FirstM, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders. New York: Biometrics Research, NewYork State Psychiatric Institute; 2002.
32. Fairburn CG, Beglin SJ. Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord. 1994;16(4):363-370.
33. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
34. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
35. GuyW. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: Psychopharmacology Research Branch, National Institute of Mental Health; 1976.
36. Stunkard AJ, Messick S. The Three-Factor Eating Questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29 (1):71-83.
37. Timmerman G. Binge Eating Scale: further assessment of validity and reliability. J Appl Biobehav Res. 1999;4(1):1-12.
38. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
39. Patton JH, StanfordMS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol. 1995;51(6):768-774.
40. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233.
41. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
42. Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale. 2009. http://cssrs.columbia.edu/docs/C-SSRS-1-14-09-Baseline.pdf. Accessed December 2, 2014.
43. McElroy SL, Guerdjikova A, Kotwal R, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007;68(3):390-398.
44. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry. 1998;155(12): 1756-1762.
45. McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry. 2000;157(6):1004-1006.
46. Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry. 2005;57(3):301-309.
47. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006;67(12):1897-1906.
48. Guerdjikova AI, McElroy SL, Kotwal R, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol. 2008;23(1):1-11.
49. Arbaizar B, Gómez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry. 2008;30(5):471-475.
50. Adler LA, Goodman DW, Kollins SH, et al; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9): 1364-1373.
51. Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L; 304 Study Group. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr. 2009;14(10):573-585.
52. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J; 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34. doi:10.1186 /1744-9081-6-34.
53. Brams M,Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977-983.
54. Adler LA, Dirks B, Deas PF, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74 (7):694-702.
55. Biederman J, Krishnan S, Zhang Y,McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450-463.
56. Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J AmAcad Child Adolesc Psychiatry. 2011;50(4):395-405.
57. Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 2009;19(6):649-662.
58. Lasser R, Dirks B, Nasrallah H, et al. Adjunctive lisdexamfetamine dimesylate treatment of predominant negative symptoms of schizophrenia in clinically stable adults maintained on atypical antipsychotic agents: a 14-week trial. Paper presented at: Third Biennial Schizophrenia International Research Conference; April 16, 2012; Florence, Italy.
59. Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014;39(6): 1388-1398.
60. Trivedi MH, Cutler AJ, Richards C, et al. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry. 2013;74(8):802-809.
61. Calero-Elvira A, Krug I, Davis K, López C, Fernández-Aranda F, Treasure J.Meta-analysis on drugs in people with eating disorders. Eur Eat Disord Rev. 2009;17(4):243-259.
62. Panagiotou OA, Contopoulos-Ioannidis DG, Papanikolaou PN, Ntzani EE, Ioannidis JP. Different black box warning labeling for same-class drugs. J Gen Intern Med. 2011;26(6):603-610.
63. Gugelmann H, Perrone J, Nelson L. Windmills and pill mills: can PDMPs tilt the prescription drug epidemic? J Med Toxicol. 2012;8(4):378-386.
64. Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. Compr Psychiatry. 2007;48 (2):124-131.
65. Grilo CM, White MA, Barnes RD, Masheb RM. Psychiatric disorder co-morbidity and correlates in an ethnically diverse sample of obese patients with binge eating disorder in primary care settings. Compr Psychiatry. 2013;54(3):209-216.
66. Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord. 2009;42 (3):228-234.